by Jan Barbořík | 12. 7. 2024
CLINICAL PERFORMANCE STUDY LIPIDICA_01-2024 Pancreatic cancer is the 10th most common type of cancer. In 2022, more than 2,400 new cases were diagnosed in the Czech Republic. Approximately 2,100 patients succumb to this disease, which is more than 87%. The main reason...
by Jan Barbořík | 1. 7. 2024
CLINICAL TRIAL OF INFURO INFURO is designed as a monocentric, prospective, randomized, double-blind, cross-over Phase II clinical trial to test the safety and tolerability of furosemide inhalation in patients with dyspnea. Dyspnea is one of the most common symptoms in...
by Jan Barbořík | 23. 11. 2023
CLINICAL TRIAL ETAPA ETAPA is a randomized, placebo-controlled trial of early targeted treatment of patent ductus arteriosus with paracetamol in extremely low birth weight infants. It is sponsored by University College Dublin and led by the principal investigator,...
by Jan Barbořík | 16. 9. 2022
CLINICAL TRIAL M.A.R.S. M.A.R.S. is a randomised double-blind placebo-controlled multicentre study of the efficacy and safety of highly diluted atropine collyrium in retarding the development of myopia in children, a phase IIIb study with three parallel arms designed...
by Jan Barbořík | 20. 7. 2022
CLINICAL TRIAL MSC-EB Safety and efficacy of allogeneic adipose-derived mesenchymal stromal cells in patients with epidermolysis bullosa: a phase I/II clinical trial MSC-EB is a phase I/II clinical trial to evaluate the safety and efficacy of a mesenchymal stromal...
